Imagenetix saw a 28% decline in sales for the second quarter of FY2010 (end-September 30), from $2.6 million in the second quarter of FY2009 to $1.9 million for the same period this fiscal year.
Net income for the second quarter was $553,000, compared to $199,000 in the second quarter a year ago. The current fiscal year period was positively impacted by a one-time buy out agreement of $1.25 million, the company noted in a press release.
Imagenetix is developing a drug, 1-tetradecanol complex (1-TDC), designed to treat and possibly arrest periodontal diseases.
.RbyOLNR6ps.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
